This article originally posted 28 October, 2011 and appeared in Issue 597, SGLT2
New First in Class SGLT2 Drugs Hit a Stumbling Block
New First in Class SGLT2 Drugs Hit a Stumbling Block
FDA delays verdict on Astra/Bristol SGLT2 diabetes pill until Jan 28th, the same day they are deciding on the possible approval of Bydureon. See this week's Item #4.
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2013 Diabetes In Control, Inc.. All rights reserved.
